TY - JOUR
T1 - Immunological imprinting
T2 - Understanding COVID-19
AU - Koutsakos, Marios
AU - Ellebedy, Ali H.
N1 - Funding Information:
M.K. is supported by funding from an Australian National Health and Medical Research Council Investigator grant, the Morningside Foundation, and a Victoria Fellowship from the Victorian Government . A.H.E. was supported in part with funding from the US National Institutes of Health (NIH), grants U01AI141990 , 1U01AI150747 , 5U01AI144616-02 , and R01AI168178-01 .
Funding Information:
M.K. has acted as a consultant for Sanofi group of companies. The Ellebedy laboratory has received funding under sponsored research agreements from Moderna, Emergent BioSolutions, and AbbVie. A.H.E. has received consulting and speaking fees from InBios International, Inc, Fimbrion Therapeutics, RGAX, Mubadala Investment Company, Moderna, Pfizer, GSK, Danaher, Third Rock Ventures, Goldman Sachs, and Morgan Stanley; is the founder of ImmuneBio Consulting and a recipient of royalties from licensing agreements with Abbvie and Leyden Laboratories B.V. The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official view of NIAID or NIH.
Publisher Copyright:
© 2023 Elsevier Inc.
PY - 2023/5/9
Y1 - 2023/5/9
N2 - Immunological imprinting generically refers to the effects prior exposures have on subsequent immune responses to, and eventually protection against, antigenically related viruses. Here, Koutsakos and Ellebedy explain different concepts and terms around imprinting and the fundamental immunological principles behind it. They also discuss the potential role imprinting may have in the context of COVID-19 vaccines.
AB - Immunological imprinting generically refers to the effects prior exposures have on subsequent immune responses to, and eventually protection against, antigenically related viruses. Here, Koutsakos and Ellebedy explain different concepts and terms around imprinting and the fundamental immunological principles behind it. They also discuss the potential role imprinting may have in the context of COVID-19 vaccines.
UR - http://www.scopus.com/inward/record.url?scp=85153605910&partnerID=8YFLogxK
U2 - 10.1016/j.immuni.2023.04.012
DO - 10.1016/j.immuni.2023.04.012
M3 - Review article
C2 - 37105169
AN - SCOPUS:85153605910
SN - 1074-7613
VL - 56
SP - 909
EP - 913
JO - Immunity
JF - Immunity
IS - 5
ER -